Evidence map›Paper›PMID 36993415›Full record

ArticlebioRxiv : the preprint server for biology2023

Assessing vaccine-mediated protection in an ultra-low dose

C R Plumlee, H W Barrett, D E Shao, K A Lien, L M Cross, S B Cohen, P T Edlefsen, K B Urdahl

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

C R PlumleeCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
H W BarrettCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
D E ShaoVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, 98109, USA.
K A LienCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
L M CrossCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
S B CohenCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
P T EdlefsenVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, 98109, USA.
K B UrdahlCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98109, USA.
Infectious Disease Research Institute · USFred Hutch Cancer Center · US

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - SARS-CoV-2 RELATED RESEARCH75N93019C00070 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI URDAHL, KEVIN · 2019 to 2025
$86.6M
Technology CoreU19AI135976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADEREM, ALAN A · 2018 to 2022
$17.0M
NIAID NIH HHS 75N93019C00070NIAID NIH HHS U19 AI135976
6 · The paper itself

Abstract

Despite widespread immunization with Bacille-Calmette-Guerin (BCG), the only currently licensed tuberculosis (TB) vaccine, TB remains a leading cause of mortality globally. There are many TB vaccine candidates in the developmental pipeline, but the lack of a robust animal model to assess vaccine efficacy has hindered our ability to prioritize candidates for human clinical trials. Here we use a murine ultra-low dose (ULD)

Identifiers

PMID36993415
PMCPMC10055404
OpenAlexW4360618654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.